N/A N=1,881 Impact of Diet on Functional Gastrointestinal Symptoms
Gastrointestinal Disorder, Functional
Primary: Most Common Triggers for Food-related GI Symptoms (Top 5) — 881; 494; 469; 460 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=158 Clinical Improvement and in Quality of Life-Functional Dyspepsia-
Psychogenic Dyspepsia
Primary: Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS) — 73.72; 65.31; 71.85; 64.89 units on a scale
Phase 4 N=74 A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
Irritable Bowel Syndrome
Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Phase 4 N=93 Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
Chronic Diarrhea of Unknown Origin
Primary: Number of Participants With a 50 Percent Decrease in Mean Stool Count — 17 Participants
Phase 2 N=20 Effect of Secretin in Functional Dyspepsia and Healthy Subjects
Dyspepsia · Healthy
Primary: Maximum Satiation — 892.5; 951.75; 655.5; 892.5 mL — p=0.12
Phase 2 N=97 A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation
Constipation
Primary: Responder for Complete Spontaneous Bowel Movement (CSBM) — 10; 14; 17; 22 participants — p=<0.05
Phase 4 N=19 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003
Phase 2 N=48 Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Within and Between Group Comparisons of Disease Severity as Determined by Irritable Bowel Syndrome-Symptom Severity Score (IBS-SSS) — 282; 309; 221; 236 units on a scale
Phase 2 N=120 An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation
Functional Gastrointestinal Disorders · Constipation
Primary: Responder of Complete Spontaneous Bowel Movement (CSBM) — 26; 5; 34; 55 participants — p=<0.05
N/A N=72 Physiotherapeutic Intervention in Children With Chronic Functional Constipation
Chronic Constipation
Primary: Frequency of Defecation. — 3.9; 5.1 days/week — p=<0.05
N/A N=48 Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Lactulose Mannitol Excretion — 512.5; 394.5; 456.8; 411 micrograms per ml
Phase 3 N=18 Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction)
Sphincter of Oddi Dysfunction
Primary: The Primary Outcome Measure Was a Patient Global Assessment of Change (PGIC) Scale. — 3.3 units on a scale
Phase 1 N=35 Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic Diarrhoea
Chronic Functional Diarrhea of Unknown Origin
Primary: Mean Change From Baseline in Blood Lead Levels During the Treatment Period and Post-treatment Follow-up Period — 0.120; 0.306; 0.095; 0.359 nanograms per millilitre…
Phase 2 N=36 Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation
Functional Constipation
Primary: Colonic Transit at 24 Hours — 2.68; 3.12; 1.93 units on a scale — p=0.059
Phase 3 N=535 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks). — 35.7; 34.7…
Phase 3 N=40 Lubiprostone and Mucus Secretion in Patients With Chronic Constipation
Constipation
Primary: Change of Mucus and Mucin Secretion in Patients With Chronic Constipation and in Controls. — 260; 133; 229; 161 mg/hour
N/A N=50 The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
N/A N=94 Lcr35 for Children With Functional Constipation
Constipation
Primary: Number of Participants With Treatment Success (≥3 Spontaneous Defecations Per Week With no Fecal Soiling — 24; 28 Participants — p=0.399
N/A N=225 Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
Irritable Bowel Syndrome · Colitis, Ulcerative · Crohn Disease
Primary: Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms — 40; 30; 23; 23 microbial species population
N/A N=120 Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence
Fecal Incontinence
Primary: Proportion of Subjects With at Least 50% Reduction in Number of Incontinent Episodes Per Week — 0.73 proportion of subjects — p=<0.0001
N/A N=25 Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder
Functional Bowel Disorders
Primary: Adequate Relief in Pain Score During Treatment — 52.6 percentage of subjects
Phase 2 N=565 Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…
Phase 3 N=224 B. Lactis HN019 for Functional Constipation
Constipation
Primary: Whole Gut Transit Time
Phase 2 N=36 Cheno Effect on Transit in Health and IBS-C
Constipation-predominant Irritable Bowel Syndrome
Primary: Colonic Geometric Center at 24 Hours (GC24) — 3.1; 3.5; 2.2 units on a scale
N/A N=27 Effects of Exercise Training on Pelvic Floor Symptoms and Function in Adults With Constipation
Constipation
Primary: Severity of Constipation Symptoms — 0.96; 0.97; 0.63; 0.67 score on a scale
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
Phase 3 N=156 Lubiprostone for Treatment of Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 — 3.1; 4.4 SBMs/week — p=0.007